272 related articles for article (PubMed ID: 34847079)
21. R-Spondins 2 and 3 Are Overexpressed in a Subset of Human Colon and Breast Cancers.
Conboy CB; Vélez-Reyes GL; Rathe SK; Abrahante JE; Temiz NA; Burns MB; Harris RS; Starr TK; Largaespada DA
DNA Cell Biol; 2021 Jan; 40(1):70-79. PubMed ID: 33320737
[TBL] [Abstract][Full Text] [Related]
22. Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo.
Kurio N; Shimo T; Fukazawa T; Takaoka M; Okui T; Hassan NM; Honami T; Hatakeyama S; Ikeda M; Naomoto Y; Sasaki A
Exp Cell Res; 2011 May; 317(8):1134-46. PubMed ID: 21338601
[TBL] [Abstract][Full Text] [Related]
23. Involvement of cell-cell and cell-matrix interactions in bone destruction induced by metastatic MDA-MB-231 human breast cancer cells in nude mice.
Nakamura H; Hiraga T; Ninomiya T; Hosoya A; Fujisaki N; Yoneda T; Ozawa H
J Bone Miner Metab; 2008; 26(6):642-7. PubMed ID: 18979165
[TBL] [Abstract][Full Text] [Related]
24. Regulation of the follistatin gene by RSPO-LGR4 signaling via activation of the WNT/β-catenin pathway in skeletal myogenesis.
Han XH; Jin YR; Tan L; Kosciuk T; Lee JS; Yoon JK
Mol Cell Biol; 2014 Feb; 34(4):752-64. PubMed ID: 24344199
[TBL] [Abstract][Full Text] [Related]
25. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
[TBL] [Abstract][Full Text] [Related]
26. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.
Wilson TJ; Nannuru KC; Futakuchi M; Sadanandam A; Singh RK
Cancer Res; 2008 Jul; 68(14):5803-11. PubMed ID: 18632634
[TBL] [Abstract][Full Text] [Related]
27. RANK ligand is a prerequisite for cancer-associated osteolytic lesions.
Kitazawa S; Kitazawa R
J Pathol; 2002 Oct; 198(2):228-36. PubMed ID: 12237883
[TBL] [Abstract][Full Text] [Related]
28. RSPO2 inhibition of RNF43 and ZNRF3 governs limb development independently of LGR4/5/6.
Szenker-Ravi E; Altunoglu U; Leushacke M; Bosso-Lefèvre C; Khatoo M; Thi Tran H; Naert T; Noelanders R; Hajamohideen A; Beneteau C; de Sousa SB; Karaman B; Latypova X; Başaran S; Yücel EB; Tan TT; Vlaminck L; Nayak SS; Shukla A; Girisha KM; Le Caignec C; Soshnikova N; Uyguner ZO; Vleminckx K; Barker N; Kayserili H; Reversade B
Nature; 2018 May; 557(7706):564-569. PubMed ID: 29769720
[TBL] [Abstract][Full Text] [Related]
29. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
30. Tetrahydrofurofuran-type lignans inhibit breast cancer-mediated bone destruction by blocking the vicious cycle between cancer cells, osteoblasts and osteoclasts.
Jun AY; Kim HJ; Park KK; Son KH; Lee DH; Woo MH; Chung WY
Invest New Drugs; 2014 Feb; 32(1):1-13. PubMed ID: 23673814
[TBL] [Abstract][Full Text] [Related]
31. RANKL interferes with osteoclastogenesis in PEG-fused U937 cells through LGR4.
Arteaga JA; Guerrero CA
Connect Tissue Res; 2023 Jan; 64(1):40-52. PubMed ID: 35726900
[TBL] [Abstract][Full Text] [Related]
32. Trolox inhibits osteolytic bone metastasis of breast cancer through both PGE2-dependent and independent mechanisms.
Lee JH; Kim B; Jin WJ; Kim JW; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2014 Sep; 91(1):51-60. PubMed ID: 24929117
[TBL] [Abstract][Full Text] [Related]
33. Tumor-supportive and osteoclastogenic changes induced by breast cancer-derived factors are reversed by inhibition of {gamma}-secretase.
Fong JE; Le Nihouannen D; Komarova SV
J Biol Chem; 2010 Oct; 285(41):31427-34. PubMed ID: 20679341
[TBL] [Abstract][Full Text] [Related]
34. Differential effects on lung and bone metastasis of breast cancer by Wnt signalling inhibitor DKK1.
Zhuang X; Zhang H; Li X; Li X; Cong M; Peng F; Yu J; Zhang X; Yang Q; Hu G
Nat Cell Biol; 2017 Oct; 19(10):1274-1285. PubMed ID: 28892080
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer exosomes contribute to pre-metastatic niche formation and promote bone metastasis of tumor cells.
Yuan X; Qian N; Ling S; Li Y; Sun W; Li J; Du R; Zhong G; Liu C; Yu G; Cao D; Liu Z; Wang Y; Qi Z; Yao Y; Wang F; Liu J; Hao S; Jin X; Zhao Y; Xue J; Zhao D; Gao X; Liang S; Li Y; Song J; Yu S; Li Y
Theranostics; 2021; 11(3):1429-1445. PubMed ID: 33391543
[No Abstract] [Full Text] [Related]
36. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
Dougall WC
Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of RANKL-Induced Osteoclastogenesis by Novel Mutant RANKL.
Jang Y; Sohn HM; Ko YJ; Hyun H; Lim W
Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33406741
[TBL] [Abstract][Full Text] [Related]
38. Engineering high-potency R-spondin adult stem cell growth factors.
Warner ML; Bell T; Pioszak AA
Mol Pharmacol; 2015; 87(3):410-20. PubMed ID: 25504990
[TBL] [Abstract][Full Text] [Related]
39. A Wnt-Independent LGR4-EGFR Signaling Axis in Cancer Metastasis.
Yue F; Jiang W; Ku AT; Young AIJ; Zhang W; Souto EP; Gao Y; Yu Z; Wang Y; Creighton CJ; Nagi C; Wang T; Hilsenbeck SG; Feng XH; Huang S; Coarfa C; Zhang XH; Liu Q; Lin X; Li Y
Cancer Res; 2021 Sep; 81(17):4441-4454. PubMed ID: 34099494
[TBL] [Abstract][Full Text] [Related]
40. RSPO2-LGR5 signaling has tumour-suppressive activity in colorectal cancer.
Wu C; Qiu S; Lu L; Zou J; Li WF; Wang O; Zhao H; Wang H; Tang J; Chen L; Xu T; Sun Z; Liao W; Luo G; Lu X
Nat Commun; 2014; 5():3149. PubMed ID: 24476626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
